Nebenwirkungen · Gazyvaro
Gazyvaro 1 000 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 24
HOS-129957 · Präparat HOS-096817
The ADRs listed in Table 12 are based on pooled safety data from two clinical studies in patients with ISN/RPS 2003 Class III or IV with or without concomitant Class V lupus nephritis, up to week 76: ● REGENCY (CA41705): a Phase III study which included 136 patients treated with Gazyvaro plus standard therapy consisting of mycophenolate mofetil (MMF) and corticosteroids. ● NOBILITY (WA29748): a Phase II study which included 64 patients treated with Gazyvaro plus standard therapy with MMF/mycophenolic acid and corticosteroids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T10:49:00Z · SHA-256 18e252f824981860d284b6a8d0590c4e67726398fe4cfebbac1cb10441aeb96a · Passage c1c62657db03f5bfb3869bd37ed9d9b3c66cdfb50557ec01d6e3eefc3ad0627b · Zeichen 19668–20215 im Abschnitt